Exscientia PLC
NASDAQ:EXAI
Intrinsic Value
Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. [ Read More ]
The intrinsic value of one EXAI stock under the Base Case scenario is 2.45 USD. Compared to the current market price of 3.95 USD, Exscientia PLC is Overvalued by 38%.
Valuation Backtest
Exscientia PLC
Run backtest to discover the historical profit from buying and selling EXAI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Exscientia PLC
Current Assets | 404.9m |
Cash & Short-Term Investments | 361.2m |
Receivables | 35.9m |
Other Current Assets | 7.9m |
Non-Current Assets | 105.8m |
Long-Term Investments | 3m |
PP&E | 67.5m |
Intangibles | 34.6m |
Other Non-Current Assets | 663k |
Current Liabilities | 65.1m |
Accounts Payable | 11.3m |
Accrued Liabilities | 22.2m |
Other Current Liabilities | 31.5m |
Non-Current Liabilities | 89.9m |
Long-Term Debt | 16.5m |
Other Non-Current Liabilities | 73.4m |
Earnings Waterfall
Exscientia PLC
Revenue
|
20.1m
GBP
|
Cost of Revenue
|
-27.4m
GBP
|
Gross Profit
|
-7.3m
GBP
|
Operating Expenses
|
-167.1m
GBP
|
Operating Income
|
-174.5m
GBP
|
Other Expenses
|
28.5m
GBP
|
Net Income
|
-146m
GBP
|
Free Cash Flow Analysis
Exscientia PLC
EXAI Profitability Score
Profitability Due Diligence
Exscientia PLC's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
Score
Exscientia PLC's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
EXAI Solvency Score
Solvency Due Diligence
Exscientia PLC's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Exscientia PLC's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EXAI Price Targets Summary
Exscientia PLC
According to Wall Street analysts, the average 1-year price target for EXAI is 8.84 USD with a low forecast of 7.07 USD and a high forecast of 10.5 USD.
Shareholder Return
EXAI Price
Exscientia PLC
Average Annual Return | -48.72% |
Standard Deviation of Annual Returns | 33.46% |
Max Drawdown | -85% |
Market Capitalization | 496.5m USD |
Shares Outstanding | 126 120 000 |
Percentage of Shares Shorted | 7.18% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.
Contact
IPO
Employees
Officers
The intrinsic value of one EXAI stock under the Base Case scenario is 2.45 USD.
Compared to the current market price of 3.95 USD, Exscientia PLC is Overvalued by 38%.